CATUG joins the European Technology Platform of Nanomedicine (ETPN) as new NanoPLATINUM member

Basel, Switzerland, October 8th, 2024 — CATUG, a global leader in Contract Research (CRO) and Contract Development and Manufacturing (CDMO), specializing in RNA therapeutics and genetic medicine, is proud to announce its partnership with the European Technology Platform for Nanomedicine (ETPN). Following the establishment of its new global headquarters, CATUG AG, in Basel, Switzerland, CATUG is further strengthening its European presence as a new NanoPLATINUM member of ETPN. This partnership marks a significant milestone in CATUG's mission to innovate in the fields of nanomedicine, drug delivery, and genetic medicine by collaborating with leading experts and institutions across Europe.

 Why ETPN? Advancing novel drug delivery and genetic medicine

Back in June 2024, CATUG delegates attended the ETPN24 event in Milan, Italy and witnessed the close collaboration among ETPN members and the shared enthusiasm within the community to help each other overcome scientific and regulatory challenges. CATUG shares the same vision of advancing science through long-term collaboration and community building with partners.

 “One of CATUG's missions is to accelerate the development and delivery of nucleic acid-based drugs from academic institutions to industry and commercialization. ETPN is a vibrant community, composed of universities, research institutes, companies, and start-ups, all passionate about the growing field of nanomedicine.” said Dr. Lin Jin, president of CATUG AG "We are excited to be part of such a collaborative network that mirrors our goal towards innovation and patient impact."

 The decision to join ETPN comes on the heels of establishing CATUG’s global headquarters at the Novartis Campus in Basel, Switzerland — a strategic move that reinforces CATUG's commitment to contributing to the European nanomedicine landscape

 “Given our shared interests in nanomedicine and our mutual desire for growth and accelerated clinical translation, joining this strong community was a natural step for us. We are proud to be ETPN members!” added Dr. Jin.

Partnering for Innovation and Impact

CATUG is looking for partners spanning from academic research to industry partners for proof of concept (PoC) studies, early Chemistry Manufacturing and Control (CMC), Investigational New Drug (IND), all the way to commercialization. Regardless of which phase of the journey your project is in, partnering with CATUG means accelerating the path from development to patient, ensuring quality and efficiency.

"I'm convinced that this collaboration will be fruitful, supporting CATUG’s growth in Europe while strengthening the European Technology Platform for Nanomedicine (ETPN) as an expert community in nucleic acid delivery through nanomedicine. Welcome aboard!" said Dr. Alexandre Ceccaldi, General Secretary of ETPN.

CATUG incorporates decades of experience, strategic vision, advanced technology platforms, and efficient operations to help our customers achieve their milestones in nucleic acid based therapeutics as well as genetic therapy products.

For more information, please visit www.catug.bio.